My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Enanta Pharmaceuticals, Inc. - Common Stock (NQ:ENTA)

15.16 +7.26 (+91.90%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 29, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 16,718,631
Open 7.150
Bid (Size) 15.02 (1)
Ask (Size) 15.03 (2)
Prev. Close 7.900
Today's Range 7.050 - 15.34
52wk Range 4.090 - 15.34
Shares Outstanding 21,055,392
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Let's take a look at the stocks that are in motion in today's session.
Intrigued by the market activity one hour before the close of the markets on Monday? Uncover the key winners and losers of today's session in our insightful analysis. 
Via Chartmill
Enanta Pharmaceuticals Stock Rises 58% – Here’s An Important Update
The company reported that a lower hospitalization rate was observed in patients treated with Zelicapavir compared to those treated with placebo, and the drug demonstrated a robust antiviral effect. 
Via Stocktwits

Performance

YTD
+171.2%
+171.2%
1 Month
+68.4%
+68.4%
3 Month
+100.5%
+100.5%
6 Month
+174.6%
+174.6%
1 Year
+46.3%
+46.3%

More News

Read More
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Enanta's RSV Pill Shows Promise In Cutting Recovery Time For High-Risk Adults
Via Benzinga
4 Analysts Have This To Say About Enanta Pharma
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
Top stock movements in today's session.
Via Chartmill
Enanta Pharmaceuticals Reports Positive Topline Results from its Phase 2b Study of Zelicapavir for the Treatment of Respiratory Syncytial Virus (RSV) in High-Risk Adults
From Enanta Pharmaceuticals, Inc.
Via Business Wire
Why Merus Shares Are Trading Higher By 38%; Here Are 20 Stocks Moving Premarket
Via Benzinga
12 Health Care Stocks Moving In Friday's After-Market Session
Via Benzinga
Curious about the stocks that are showing activity after the closing bell on Friday?
Via Chartmill
Enanta Pharmaceuticals to Present Topline Results from its Phase 2b Study Evaluating Zelicapavir for the Treatment of Respiratory Syncytial Virus (RSV) in High-Risk Adults
From Enanta Pharmaceuticals, Inc.
Via Business Wire
Enanta Pharmaceuticals Announces the Passing of its Beloved and Respected Longtime Chief Financial and Administrative Officer Paul J. Mellett Jr.
From Enanta Pharmaceuticals, Inc.
Via Business Wire
Enanta Pharmaceuticals to Participate in September Investor Conferences
From Enanta Pharmaceuticals, Inc.
Via Business Wire
Enanta Pharmaceuticals Files Patent Infringement Suit Against Pfizer in the Unified Patent Court of the European Union
From Enanta Pharmaceuticals, Inc.
Via Business Wire
Enanta Pharmaceuticals Reports Financial Results for its Fiscal Third Quarter Ended June 30, 2025
From Enanta Pharmaceuticals, Inc.
Via Business Wire
Enanta Pharmaceuticals to Participate in the H.C. Wainwright & Co. “HCW@Home” Series
From Enanta Pharmaceuticals, Inc.
Via Business Wire
Enanta Pharmaceuticals to Participate in Baird’s Biotech Discovery Series
From Enanta Pharmaceuticals, Inc.
Via Business Wire
FDA Expands AbbVie's Mavyret Label To Include Pediatric Patients With Hepatitis C Infection
Via Benzinga
Enanta Pharmaceuticals’ Partner AbbVie Receives U.S. FDA Approval of an Expanded Indication for MAVYRET® (glecaprevir/pibrentasvir) as the First and Only Treatment for People with Acute Hepatitis C Virus
From Enanta Pharmaceuticals, Inc.
Via Business Wire
Enanta Pharmaceuticals to Present at the Jefferies Global Healthcare Conference
From Enanta Pharmaceuticals, Inc.
Via Business Wire
Enanta Pharmaceuticals Announces Data from its Phase 2 Study of Zelicapavir in Children with Respiratory Syncytial Virus to be Presented at the 43rd Annual ESPID Meeting
From Enanta Pharmaceuticals, Inc.
Via Business Wire
Enanta Pharmaceuticals Reports Financial Results for its Fiscal Second Quarter Ended March 31, 2025
From Enanta Pharmaceuticals, Inc.
Via Business Wire
Enanta Pharmaceuticals Announces Respiratory Syncytial Virus Data Presentation at ESCMID Global 2025
From Enanta Pharmaceuticals, Inc.
Via Business Wire
Enanta Pharmaceuticals to Present at the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference
From Enanta Pharmaceuticals, Inc.
Via Business Wire

Frequently Asked Questions

Is Enanta Pharmaceuticals, Inc. - Common Stock publicly traded?
Yes, Enanta Pharmaceuticals, Inc. - Common Stock is publicly traded.
What exchange does Enanta Pharmaceuticals, Inc. - Common Stock trade on?
Enanta Pharmaceuticals, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Enanta Pharmaceuticals, Inc. - Common Stock?
The ticker symbol for Enanta Pharmaceuticals, Inc. - Common Stock is ENTA on the Nasdaq Stock Market
What is the current price of Enanta Pharmaceuticals, Inc. - Common Stock?
The current price of Enanta Pharmaceuticals, Inc. - Common Stock is 15.16
When was Enanta Pharmaceuticals, Inc. - Common Stock last traded?
The last trade of Enanta Pharmaceuticals, Inc. - Common Stock was at 09/29/25 04:00 PM ET
What is the market capitalization of Enanta Pharmaceuticals, Inc. - Common Stock?
The market capitalization of Enanta Pharmaceuticals, Inc. - Common Stock is 319.20M
How many shares of Enanta Pharmaceuticals, Inc. - Common Stock are outstanding?
Enanta Pharmaceuticals, Inc. - Common Stock has 319M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.